The estimated Net Worth of Steven Lazarus is at least $21.3 Milion dollars as of 25 February 2004. Steven Lazarus owns over 10,000 units of Illumina Inc stock worth over $18,642,487 and over the last 21 years Steven sold ILMN stock worth over $2,642,410.
Steven has made over 5 trades of the Illumina Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Steven sold 10,000 units of ILMN stock worth $642,200 on 25 February 2004.
The largest trade Steven's ever made was selling 10,000 units of Illumina Inc stock on 25 February 2004 worth over $642,200. On average, Steven trades about 4,444 units every 22 days since 2003. As of 25 February 2004 Steven still owns at least 149,343 units of Illumina Inc stock.
You can see the complete history of Steven Lazarus stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is 8725 WEST HIGGINS ROAD, SUITE 290, CHICAGO, IL, 60631.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley a Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: